MASSACHUSETTS GENERAL HOSPITAL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
2.4k
Trial Phases
6 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (2047 trials with phase data)• Click on a phase to view related trials
Momelotinib During and After HCT in Myelofibrosis
- Conditions
- MyelofibrosisHematopoietic Cell Transplantation (HCT)
- Interventions
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT07104799
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
ActiveGirls: Physical Activity, Hormone Health, and Diabetes Risk in Early Adolescence
- Conditions
- PCOS (Polycystic Ovary Syndrome)PubertyInsulin ResistancePhysical Activity
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07102797
A Test of Efficacy and Foot Position Alteration in Patients Wearing Good Feet Arch Supports for the Treatment of Pain
- Conditions
- Plantar Fasciitis of Both FeetMetatarsalgiaMorton NeuromaHallux Valgus DeformityLow Back PainAnkle PainKnee Pain
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT07103070
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
- Conditions
- Colorectal AdenomaColorectal Cancer Prevention
- Interventions
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07095517
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Building Connections
- Conditions
- Cancer ColorectalCancer CervixDepression, AnxietyObesity
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 3600
- Registration Number
- NCT07091032
- Locations
- 🇺🇸
Disparities Research Unit, Massachusetts General Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 488
- Next
News
Mass General Brigham Launches Clinical Trials for Haystack MRD ctDNA Test in Head and Neck and Skin Cancers
Mass General Brigham has initiated two prospective clinical trials to evaluate Haystack MRD, a highly sensitive circulating tumor DNA test, for guiding postoperative treatment decisions in cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma.
Harvard Study Reveals Lithium Deficiency as Potential Driver of Alzheimer's Disease
Harvard researchers found that people with Alzheimer's disease have 36% lower lithium levels in their prefrontal cortex compared to those without cognitive decline.
GLP-1 Receptor Agonists Naturally Restore Testosterone Levels in Men with Obesity and Type 2 Diabetes
A retrospective study of 110 men with obesity or Type 2 diabetes found that GLP-1 receptor agonists like semaglutide and tirzepatide can naturally restore testosterone levels over 18 months of treatment.
UAEU Researcher Secures Four Patents for Computational Drug Design and Medical Device Innovations
Dr. Alya A. Arabi from United Arab Emirates University has been granted four patents spanning computational drug design and medical device development.
Novel Royalty-Based Investment Fund Proposes New Model for ALS Drug Development
Researchers from MIT, Massachusetts General Hospital, and Boston University propose a novel "Fund of Adaptive Royalties" (FAR) that finances half the cost of adaptive platform trials in exchange for future drug royalties.
Duvelisib-Romidepsin Combination Shows 61% Response Rate in Relapsed T-Cell Lymphomas
A real-world study by Mass General Brigham's PETAL Consortium demonstrated that the combination of duvelisib and romidepsin achieved a 61% overall response rate in 38 patients with relapsed/refractory T-cell lymphomas.
Alzamend Neuro Completes $5 Million Financing to Advance Five Phase II Trials for AL001 Lithium Therapy
Alzamend Neuro completed a $5 million private placement months ahead of schedule to fund five Phase II clinical trials of AL001 "Lithium in Brain" studies at Massachusetts General Hospital.
Penumbra Completes Enrollment in Landmark STORM-PE Trial Testing Thrombectomy for Pulmonary Embolism
Penumbra has completed enrollment of 100 patients in the pivotal STORM-PE randomized controlled trial, comparing computer assisted vacuum thrombectomy plus anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism.
Fidaxomicin Demonstrates Superior Efficacy in Reducing C. difficile Recurrence Among High-Risk Patients
Multiple studies presented at MAD-ID 2025 demonstrate fidaxomicin's superior efficacy over vancomycin in preventing C. difficile infection recurrence among high-risk patient populations.
Psilocybin Clinical Trial Targets Treatment-Resistant IBS in Groundbreaking Gastroenterology Study
Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).